

Charles Swanton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4454222/publications.pdf>

Version: 2024-02-01

293
papers

67,802
citations

1994

101
h-index

834

245
g-index

332
all docs

332
docs citations

332
times ranked

83166
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. <i>Seminars in Cancer Biology</i> , 2022, 84, 89-102. | 9.6 | 21 |
| 2 | Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients. <i>Lancet</i> , The, 2022, 399, 800-802. | 13.7 | 35 |
| 3 | Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. <i>Lancet</i> , The, 2022, 399, 905-907. | 13.7 | 60 |
| 4 | Three-dose vaccination elicits neutralising antibodies against omicron. <i>Lancet</i> , The, 2022, 399, 715-717. | 13.7 | 82 |
| 5 | Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. <i>Cancer Cell</i> , 2022, 40, 114-116. | 16.8 | 50 |
| 6 | Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. <i>Cancer Discovery</i> , 2022, 12, 654-669. | 9.4 | 34 |
| 7 | Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. <i>Nature Ecology and Evolution</i> , 2022, 6, 88-102. | 7.8 | 30 |
| 8 | Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities. <i>Cancer Research</i> , 2022, 82, 1589-1602. | 0.9 | 7 |
| 9 | The translational challenges of precision oncology. <i>Cancer Cell</i> , 2022, 40, 458-478. | 16.8 | 38 |
| 10 | A local human V α 1 T cell population is associated with survival in nonsmall-cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 696-709. | 13.2 | 39 |
| 11 | CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2022, 14, . | 12.4 | 8 |
| 12 | Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. <i>Nature Biotechnology</i> , 2022, 40, 1624-1633. | 17.5 | 31 |
| 13 | Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy. <i>Epilepsy and Behavior</i> , 2021, 115, 107602. | 1.7 | 11 |
| 14 | Consequences of COVID-19 for cancer care – a CRUK perspective. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 3-4. | 27.6 | 65 |
| 15 | A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms. <i>Mutagenesis</i> , 2021, 36, 75-86. | 2.6 | 19 |
| 16 | Understanding the impact of immune-mediated selection on lung cancer evolution. <i>British Journal of Cancer</i> , 2021, 124, 1615-1617. | 6.4 | 5 |
| 17 | Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> , 2021, 184, 596-614.e14. | 28.9 | 485 |
| 18 | A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 1754-1773. | 9.4 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. <i>Nature Communications</i> , 2021, 12, 1751. | 12.8 | 66 |
| 20 | Tracking Cancer Evolution through the Disease Course. <i>Cancer Discovery</i> , 2021, 11, 916-932. | 9.4 | 77 |
| 21 | AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. <i>Nature</i> , 2021, 592, 799-803. | 27.8 | 78 |
| 22 | Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. <i>Cell</i> , 2021, 184, 2239-2254.e39. | 28.9 | 260 |
| 23 | Selection of metastasis competent subclones in the tumour interior. <i>Nature Ecology and Evolution</i> , 2021, 5, 1033-1045. | 7.8 | 50 |
| 24 | Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324. | 7.0 | 44 |
| 25 | Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. <i>Nature Medicine</i> , 2021, 27, 1362-1366. | 30.7 | 70 |
| 26 | Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution. <i>Cancer Discovery</i> , 2021, 11, 2456-2473. | 9.4 | 74 |
| 27 | Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. <i>Lancet, The</i> , 2021, 397, 2331-2333. | 13.7 | 490 |
| 28 | E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion. <i>Oncogene</i> , 2021, 40, 5567-5578. | 5.9 | 3 |
| 29 | Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. <i>ELife</i> , 2021, 10, . | 6.0 | 42 |
| 30 | AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. <i>Lancet, The</i> , 2021, 398, 207-209. | 13.7 | 112 |
| 31 | Capturing cancer evolution using genetically engineered mouse models (GEMMs). <i>Trends in Cell Biology</i> , 2021, 31, 1007-1018. | 7.9 | 20 |
| 32 | Cancer evolution: Darwin and beyond. <i>EMBO Journal</i> , 2021, 40, e108389. | 7.8 | 118 |
| 33 | Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology, The</i> , 2021, 22, 1290-1300. | 10.7 | 178 |
| 34 | Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560. | 27.8 | 36 |
| 35 | Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. <i>Lancet, The</i> , 2021, 398, 1038-1041. | 13.7 | 73 |
| 36 | 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. <i>Nature Communications</i> , 2021, 12, 5606. | 12.8 | 76 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts. <i>Gastroenterology</i> , 2021, 161, 1179-1193. | 1.3 | 62 |
| 38 | Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662. | 1.1 | 274 |
| 39 | Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. <i>Open Biology</i> , 2021, 11, 200247. | 3.6 | 28 |
| 40 | Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. <i>Cancer Discovery</i> , 2021, 11, 1212-1227. | 9.4 | 139 |
| 41 | Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. <i>Nature Communications</i> , 2021, 12, 5906. | 12.8 | 36 |
| 42 | Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1321-1337. | 13.2 | 66 |
| 43 | Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320. | 13.2 | 123 |
| 44 | Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11. | 16.8 | 126 |
| 45 | Intratumor heterogeneity reflects clinical disease course. <i>Nature Cancer</i> , 2020, 1, 3-6. | 13.2 | 44 |
| 46 | Scientific consensus on the COVID-19 pandemic: we need to act now. <i>Lancet</i> , The, 2020, 396, e71-e72. | 13.7 | 189 |
| 47 | The National Lung Matrix Trial of personalized therapy in lung cancer. <i>Nature</i> , 2020, 583, 807-812. | 27.8 | 96 |
| 48 | Cancer Research: The Lessons to Learn from COVID-19. <i>Cancer Discovery</i> , 2020, 10, 1263-1266. | 9.4 | 25 |
| 49 | Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer. <i>Cancer Discovery</i> , 2020, 10, 1489-1499. | 9.4 | 60 |
| 50 | Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. <i>Lancet Oncology</i> , The, 2020, 21, 1035-1044. | 10.7 | 359 |
| 51 | Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. <i>Nature Communications</i> , 2020, 11, 3800. | 12.8 | 61 |
| 52 | Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132. | 27.8 | 221 |
| 53 | MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. <i>Nature Communications</i> , 2020, 11, 4527. | 12.8 | 32 |
| 54 | Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. <i>Science</i> , 2020, 370, 1339-1343. | 12.6 | 735 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Genomic landscape of platinum resistant and sensitive testicular cancers. Nature Communications, 2020, 11, 2189. | 12.8 | 43 |
| 56 | Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 2020, 26, 1054-1062. | 30.7 | 181 |
| 57 | Protecting "covid protected" cancer hubs. BMJ, The, 2020, 369, m2062. | 6.0 | 4 |
| 58 | Scalable and robust SARS-CoV-2 testing in an academic center. Nature Biotechnology, 2020, 38, 927-931. | 17.5 | 32 |
| 59 | Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550. | 6.4 | 51 |
| 60 | Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nature Genetics, 2020, 52, 283-293. | 21.4 | 168 |
| 61 | Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. Lancet, The, 2020, 396, e6-e7. | 13.7 | 196 |
| 62 | Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Reports, 2020, 30, 481-496.e6. | 6.4 | 111 |
| 63 | Securing the future of the clinician-scientist. Nature Cancer, 2020, 1, 139-141. | 13.2 | 20 |
| 64 | Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology, 2020, 31, 745-759. | 1.2 | 770 |
| 65 | COVID-19: the case for health-care worker screening to prevent hospital transmission. Lancet, The, 2020, 395, 1418-1420. | 13.7 | 368 |
| 66 | Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. Nature Communications, 2020, 11, 1792. | 12.8 | 25 |
| 67 | Take lessons from cancer evolution to the clinic. Nature, 2020, 581, 382-383. | 27.8 | 19 |
| 68 | The T cell differentiation landscape is shaped by tumour mutations in lung cancer. Nature Cancer, 2020, 1, 546-561. | 13.2 | 74 |
| 69 | Neoantigen quality, not quantity. Science Translational Medicine, 2019, 11, . | 12.4 | 98 |
| 70 | UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell, 2019, 179, 219-235.e21. | 28.9 | 270 |
| 71 | Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947. | 1.1 | 69 |
| 72 | Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nature Medicine, 2019, 25, 1549-1559. | 30.7 | 147 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-------|-----------|
| 73 | Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. <i>Nature Medicine</i> , 2019, 25, 1534-1539. | 30.7 | 146 |
| 74 | A clonal expression biomarker associates with lung cancer mortality. <i>Nature Medicine</i> , 2019, 25, 1540-1548. | 30.7 | 75 |
| 75 | Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. <i>Nature Medicine</i> , 2019, 25, 517-525. | 30.7 | 178 |
| 76 | Neoantigen-directed immune escape in lung cancer evolution. <i>Nature</i> , 2019, 567, 479-485. | 27.8 | 639 |
| 77 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2019, 20, 518-530. | 10.7 | 362 |
| 78 | Resolving genetic heterogeneity in cancer. <i>Nature Reviews Genetics</i> , 2019, 20, 404-416. | 16.3 | 443 |
| 79 | Artificial intelligence in cancer imaging: Clinical challenges and applications. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 127-157. | 329.8 | 965 |
| 80 | Prospective analysis of 895 patients on a UK Genomics Review Board. <i>ESMO Open</i> , 2019, 4, e000469. | 4.5 | 22 |
| 81 | An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood. <i>Methods in Molecular Biology</i> , 2019, 1884, 15-42. | 0.9 | 15 |
| 82 | The function and dysfunction of memory $CD8^{+}$ T cells in tumor immunity. <i>Immunological Reviews</i> , 2018, 283, 194-212. | 6.0 | 121 |
| 83 | Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors. <i>International Journal of Cancer</i> , 2018, 143, 160-166. | 5.1 | 18 |
| 84 | Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4. | 16.8 | 827 |
| 85 | Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. <i>Cell</i> , 2018, 173, 611-623.e17. | 28.9 | 398 |
| 86 | Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. <i>Cell</i> , 2018, 173, 595-610.e11. | 28.9 | 472 |
| 87 | Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. <i>Cell</i> , 2018, 173, 581-594.e12. | 28.9 | 609 |
| 88 | Chromosomal instability drives metastasis through a cytosolic DNA response. <i>Nature</i> , 2018, 553, 467-472. | 27.8 | 1,002 |
| 89 | Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. <i>Annals of Oncology</i> , 2018, 29, 271-279. | 1.2 | 106 |
| 90 | Cancer therapeutics through an evolutionary lens. <i>Journal of the Royal Society of Medicine</i> , 2018, 111, 8-14. | 2.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Determinants and clinical implications of chromosomal instability in cancer. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 139-150. | 27.6 | 272 |
| 92 | The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. <i>Annals of Oncology</i> , 2018, 29, 30-35. | 1.2 | 118 |
| 93 | Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. <i>Cancer Cell</i> , 2018, 33, 649-663.e4. | 16.8 | 448 |
| 94 | Reply to J.J. Tao et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2451-2451. | 1.6 | 1 |
| 95 | Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 536-542. | 1.6 | 362 |
| 96 | Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. <i>Journal of Experimental Medicine</i> , 2018, 215, 2748-2759. | 8.5 | 34 |
| 97 | Kidney cancer: The next decade. <i>Journal of Experimental Medicine</i> , 2018, 215, 2477-2479. | 8.5 | 125 |
| 98 | Early stage NSCLC "challenges to implementing ctDNA-based screening and MRD detection. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 577-586. | 27.6 | 281 |
| 99 | Genomic instability in mutant p53 cancer cells upon entotic engulfment. <i>Nature Communications</i> , 2018, 9, 3070. | 12.8 | 64 |
| 100 | BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer. <i>Cancer Cell</i> , 2017, 31, 79-93. | 16.8 | 83 |
| 101 | APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability. <i>Cancer Discovery</i> , 2017, 7, 218-233. | 9.4 | 87 |
| 102 | Renal cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17009. | 30.5 | 1,727 |
| 103 | Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. <i>Cell</i> , 2017, 168, 613-628. | 28.9 | 1,957 |
| 104 | Evolutionary dynamics in pre-invasive neoplasia. <i>Current Opinion in Systems Biology</i> , 2017, 2, 1-8. | 2.6 | 12 |
| 105 | Constraints in cancer evolution. <i>Biochemical Society Transactions</i> , 2017, 45, 1-13. | 3.4 | 29 |
| 106 | Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788. | 21.4 | 112 |
| 107 | Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. <i>Immunity</i> , 2017, 46, 577-586. | 14.3 | 323 |
| 108 | Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. <i>Annals of Oncology</i> , 2017, 28, 1448-1456. | 1.2 | 283 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | The future of UK healthcare: problems and potential solutions to a system in crisis. <i>Annals of Oncology</i> , 2017, 28, 1751-1755. | 1.2 | 25 |
| 110 | Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. <i>Nature</i> , 2017, 545, 446-451. | 27.8 | 1,287 |
| 111 | Tracking the Evolution of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2109-2121. | 27.0 | 1,786 |
| 112 | Implications of cancer evolution for drug development. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 441-442. | 46.4 | 28 |
| 113 | Evolving adoptive cellular therapies in urological malignancies. <i>Lancet Oncology</i> , The, 2017, 18, e341-e353. | 10.7 | 22 |
| 114 | Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. <i>Neuro-Oncology</i> , 2017, 19, 1058-1067. | 1.2 | 38 |
| 115 | Cellular Prion Protein PrPC and Ecto-5'-Nucleotidase Are Markers of the Cellular Stress Response to Aneuploidy. <i>Cancer Research</i> , 2017, 77, 2914-2926. | 0.9 | 7 |
| 116 | Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026617. | 6.2 | 59 |
| 117 | Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> , 2017, 171, 1259-1271.e11. | 28.9 | 968 |
| 118 | Cancer Evolution Constrained by the Immune Microenvironment. <i>Cell</i> , 2017, 170, 825-827. | 28.9 | 60 |
| 119 | Classifying the evolutionary and ecological features of neoplasms. <i>Nature Reviews Cancer</i> , 2017, 17, 605-619. | 28.4 | 303 |
| 120 | Tumor Evolution as a Therapeutic Target. <i>Cancer Discovery</i> , 2017, 7, 805-817. | 9.4 | 158 |
| 121 | Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. <i>Annals of Oncology</i> , 2017, 28, 2472-2480. | 1.2 | 45 |
| 122 | The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset Released. <i>Cancer Discovery</i> , 2017, 7, 796-798. | 9.4 | 14 |
| 123 | Origins of lymphatic and distant metastases in human colorectal cancer. <i>Science</i> , 2017, 357, 55-60. | 12.6 | 358 |
| 124 | Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. <i>Nature Communications</i> , 2017, 8, 1773. | 12.8 | 54 |
| 125 | Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. <i>Nature Genetics</i> , 2017, 49, 1693-1704. | 21.4 | 423 |
| 126 | Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1009-1021. | 10.7 | 716 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution. Annual Review of Cancer Biology, 2017, 1, 223-240. | 4.5 | 20 |
| 128 | The Role of Aneuploidy in Cancer Evolution. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a028373. | 6.2 | 189 |
| 129 | Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene, 2017, 36, 746-755. | 5.9 | 98 |
| 130 | The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology, 2017, 71, 237-246. | 1.9 | 62 |
| 131 | Cyclin D mediates tolerance of genome-doubling in cancers with functional p53. Annals of Oncology, 2017, 28, 149-156. | 1.2 | 43 |
| 132 | The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Medicine, 2017, 15, 133. | 5.5 | 166 |
| 133 | Quantification of tumour evolution and heterogeneity via Bayesian epiallele detection. BMC Bioinformatics, 2017, 18, 354. | 2.6 | 15 |
| 134 | Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.. Journal of Clinical Oncology, 2017, 35, 402-402. | 1.6 | 49 |
| 135 | Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e141-e149. | 3.8 | 63 |
| 136 | Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Medicine, 2016, 13, e1002136. | 8.4 | 28 |
| 137 | Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Annals of Oncology, 2016, 27, 1443-1448. | 1.2 | 79 |
| 138 | Metastasis as an evolutionary process. Science, 2016, 352, 169-175. | 12.6 | 497 |
| 139 | Re-Evaluating Clonal Dominance in Cancer Evolution. Trends in Cancer, 2016, 2, 263-276. | 7.4 | 39 |
| 140 | International cancer seminars: a focus on kidney cancer. Annals of Oncology, 2016, 27, 1382-1385. | 1.2 | 18 |
| 141 | Clinical Implications of Genomic Discoveries in Lung Cancer. New England Journal of Medicine, 2016, 374, 1864-1873. | 27.0 | 235 |
| 142 | Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nature Biotechnology, 2016, 34, 1037-1045. | 17.5 | 279 |
| 143 | Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet, The, 2016, 388, 1002-1011. | 13.7 | 132 |
| 144 | DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biology, 2016, 17, 185. | 8.8 | 140 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. <i>Genome Biology</i> , 2016, 17, 31. | 8.8 | 917 |
| 146 | A comprehensive survey of the mutagenic impact of common cancer cytotoxics. <i>Genome Biology</i> , 2016, 17, 99. | 8.8 | 150 |
| 147 | Environmental emissions, public health and lung cancer risk. <i>Annals of Oncology</i> , 2016, 27, 211-212. | 1.2 | 9 |
| 148 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222. | 9.1 | 4,701 |
| 149 | RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress. <i>Oncogene</i> , 2016, 35, 4009-4019. | 5.9 | 37 |
| 150 | Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy. <i>Cancer Discovery</i> , 2016, 6, 122-124. | 9.4 | 13 |
| 151 | Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 862-867. | 1.2 | 137 |
| 152 | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , 2016, 351, 1463-1469. | 12.6 | 2,445 |
| 153 | The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". <i>PLoS Medicine</i> , 2016, 13, e1002204. | 8.4 | 119 |
| 154 | Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e141-e149. | 3.8 | 49 |
| 155 | TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen. <i>BMC Medical Genomics</i> , 2015, 8, 58. | 1.5 | 49 |
| 156 | SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. <i>Oncogene</i> , 2015, 34, 5699-5708. | 5.9 | 147 |
| 157 | How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. <i>Current Opinion in Urology</i> , 2015, 25, 358-366. | 1.8 | 34 |
| 158 | Evolutionary Precision Medicine: A Role for Repeat Epidermal Growth Factor Receptor Analysis in <i>ALK</i> -Rearranged Lung Adenocarcinoma?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3681-3683. | 1.6 | 9 |
| 159 | SnapShot: Renal Cell Carcinoma. <i>Cell</i> , 2015, 163, 1556-1556.e1. | 28.9 | 50 |
| 160 | Tetraploidy and CIN: a dangerous combination. <i>Cell Cycle</i> , 2015, 14, 3217-3217. | 2.6 | 6 |
| 161 | Cancer Evolution Constrained by Mutation Order. <i>New England Journal of Medicine</i> , 2015, 372, 661-663. | 27.0 | 22 |
| 162 | Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution. <i>Cancer Cell</i> , 2015, 27, 15-26. | 16.8 | 923 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | Can oncology recapitulate paleontology? Lessons from species extinctions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 273-285. | 27.6 | 31 |
| 164 | Translational Implications of Tumor Heterogeneity. <i>Clinical Cancer Research</i> , 2015, 21, 1258-1266. | 7.0 | 424 |
| 165 | Toward understanding and exploiting tumor heterogeneity. <i>Nature Medicine</i> , 2015, 21, 846-853. | 30.7 | 604 |
| 166 | Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy. <i>Cancer Discovery</i> , 2015, 5, 821-831. | 9.4 | 227 |
| 167 | Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. <i>Annals of Oncology</i> , 2015, 26, 1340-1346. | 1.2 | 61 |
| 168 | Analysis of intratumor heterogeneity unravels lung cancer evolution. <i>Molecular and Cellular Oncology</i> , 2015, 2, e985549. | 0.7 | 28 |
| 169 | Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome. <i>Annals of Oncology</i> , 2015, 26, 880-887. | 1.2 | 37 |
| 170 | APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. <i>Cancer Discovery</i> , 2015, 5, 704-712. | 9.4 | 392 |
| 171 | Clinical management of breast cancer heterogeneity. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 381-394. | 27.6 | 400 |
| 172 | Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. <i>Science Translational Medicine</i> , 2015, 7, 283ra54. | 12.4 | 589 |
| 173 | Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. <i>Nature Communications</i> , 2015, 6, 6336. | 12.8 | 100 |
| 174 | Inferring mutational timing and reconstructing tumour evolutionary histories. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 264-275. | 7.4 | 48 |
| 175 | New approaches for improving outcomes in breast cancer in Europe. <i>Breast</i> , 2015, 24, 321-330. | 2.2 | 42 |
| 176 | The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 2464-2469. | 1.2 | 58 |
| 177 | Tracking tumour evolution through liquid biopsy. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 565-566. | 27.6 | 4 |
| 178 | Relapse models for clear cell renal carcinoma. <i>Lancet Oncology</i> , The, 2015, 16, e376-e378. | 10.7 | 3 |
| 179 | Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications. <i>European Urology</i> , 2015, 67, 729-737. | 1.9 | 100 |
| 180 | The Genome of the Chicken DT40 Bursal Lymphoma Cell Line. <i>G3: Genes, Genomes, Genetics</i> , 2014, 4, 2231-2240. | 1.8 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 181 | 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2014, 20, 3945-3954. | 7.0 | 105 |
| 182 | Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance. <i>Cancer Research</i> , 2014, 74, 2946-2961. | 0.9 | 20 |
| 183 | Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. <i>PLoS Biology</i> , 2014, 12, e1001906. | 5.6 | 185 |
| 184 | Multidisciplinary urological engagement in translational renal cancer research. <i>BJU International</i> , 2014, 114, 474-475. | 2.5 | 2 |
| 185 | Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution. <i>Cancer Discovery</i> , 2014, 4, 175-185. | 9.4 | 359 |
| 186 | Prioritizing targets for precision cancer medicine. <i>Annals of Oncology</i> , 2014, 25, 2295-2303. | 1.2 | 146 |
| 187 | Epigenetic Noise Fuels Cancer Evolution. <i>Cancer Cell</i> , 2014, 26, 775-776. | 16.8 | 12 |
| 188 | Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. <i>Genome Biology</i> , 2014, 15, 433. | 8.8 | 69 |
| 189 | Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data. <i>Genome Biology</i> , 2014, 15, 470. | 8.8 | 11 |
| 190 | Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. <i>European Urology</i> , 2014, 66, 936-948. | 1.9 | 141 |
| 191 | Chromosomal Instability Selects Gene Copy-Number Variants Encoding Core Regulators of Proliferation in ER+ Breast Cancer. <i>Cancer Research</i> , 2014, 74, 4853-4863. | 0.9 | 66 |
| 192 | Spatial and temporal cancer evolution: causes and consequences of tumour diversity. <i>Clinical Medicine</i> , 2014, 14, s33-s37. | 1.9 | 23 |
| 193 | Chromosomal Instability, Aneuploidy, and Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 161. | 2.8 | 23 |
| 194 | Cancer evolution: the final frontier of precision medicine?. <i>Annals of Oncology</i> , 2014, 25, 549-551. | 1.2 | 31 |
| 195 | Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. <i>Nature Genetics</i> , 2014, 46, 225-233. | 21.4 | 1,103 |
| 196 | Implications of intratumour heterogeneity for treatment stratification. <i>Journal of Pathology</i> , 2014, 232, 264-273. | 4.5 | 53 |
| 197 | Ccdc13; a novel human centriolar satellite protein required for ciliogenesis and genome stability. <i>Journal of Cell Science</i> , 2014, 127, 2910-9. | 2.0 | 35 |
| 198 | The evolution of the unstable cancer genome. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 61-67. | 3.3 | 62 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 199 | Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 221-229. | 2.5 | 10 |
| 200 | Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. <i>Genome Biology</i> , 2014, 15, 453. | 8.8 | 180 |
| 201 | Combined inhibition of BRAF and MEK in melanoma patients. <i>Lancet Oncology</i> , The, 2014, 15, 908-910. | 10.7 | 6 |
| 202 | Cancer: Evolution Within a Lifetime. <i>Annual Review of Genetics</i> , 2014, 48, 215-236. | 7.6 | 196 |
| 203 | Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. <i>Science</i> , 2014, 346, 251-256. | 12.6 | 962 |
| 204 | Tumour heterogeneity and the evolution of polyclonal drug resistance. <i>Molecular Oncology</i> , 2014, 8, 1095-1111. | 4.6 | 347 |
| 205 | SAFIR01: steps towards precision treatment in breast cancer. <i>Lancet Oncology</i> , The, 2014, 15, 242-243. | 10.7 | 8 |
| 206 | Response to Bakhoun et al.. <i>Current Biology</i> , 2014, 24, R150. | 3.9 | 2 |
| 207 | HELO promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis. <i>Nature</i> , 2013, 502, 381-384. | 27.8 | 94 |
| 208 | Computational optimisation of targeted DNA sequencing for cancer detection. <i>Scientific Reports</i> , 2013, 3, 3309. | 3.3 | 20 |
| 209 | The causes and consequences of genetic heterogeneity in cancer evolution. <i>Nature</i> , 2013, 501, 338-345. | 27.8 | 1,969 |
| 210 | A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. <i>Breast Cancer Research</i> , 2013, 15, R110. | 5.0 | 86 |
| 211 | Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. <i>Genome Medicine</i> , 2013, 5, 101. | 8.2 | 38 |
| 212 | Cancer heterogeneity and "The Struggle for Existence": Diagnostic and analytical challenges. <i>Cancer Letters</i> , 2013, 340, 220-226. | 7.2 | 26 |
| 213 | Plasma-Derived Tumor DNA Analysis at Whole-Genome Resolution. <i>Clinical Chemistry</i> , 2013, 59, 6-8. | 3.2 | 6 |
| 214 | Modelling the evolution of genetic instability during tumour progression. <i>Evolutionary Applications</i> , 2013, 6, 20-33. | 3.1 | 41 |
| 215 | <sc>LRIG1</sc> regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development. <i>Journal of Pathology</i> , 2013, 229, 608-620. | 4.5 | 34 |
| 216 | A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 691-698. | 2.5 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 217 | Taxane benefit in breast cancer—a role for grade and chromosomal stability. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 357-364. | 27.6 | 48 |
| 218 | Replication stress links structural and numerical cancer chromosomal instability. <i>Nature</i> , 2013, 494, 492-496. | 27.8 | 694 |
| 219 | Adapting Clinical Paradigms to the Challenges of Cancer Clonal Evolution. <i>American Journal of Pathology</i> , 2013, 182, 1962-1971. | 3.8 | 40 |
| 220 | Parallel evolution of tumour subclones mimics diversity between tumours. <i>Journal of Pathology</i> , 2013, 230, 356-364. | 4.5 | 79 |
| 221 | Cancer heterogeneity: implications for targeted therapeutics. <i>British Journal of Cancer</i> , 2013, 108, 479-485. | 6.4 | 753 |
| 222 | Tumour heterogeneity and immune-modulation. <i>Current Opinion in Pharmacology</i> , 2013, 13, 497-503. | 3.5 | 37 |
| 223 | Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. <i>Annals of Oncology</i> , 2013, 24, 647-654. | 1.2 | 117 |
| 224 | Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 971-972. | 1.6 | 6 |
| 225 | Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. <i>Journal of Pathology</i> , 2013, 231, 424-432. | 4.5 | 93 |
| 226 | Molecular Profiling and the Reclassification of Cancer: Divide and Conquer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 127-134. | 3.8 | 28 |
| 227 | Molecular Profiling and the Reclassification of Cancer: Divide and Conquer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 127-134. | 3.8 | 13 |
| 228 | The CIN4 Chromosomal Instability qPCR Classifier Defines Tumor Aneuploidy and Stratifies Outcome in Grade 2 Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e56707. | 2.5 | 28 |
| 229 | The centriolar satellite protein Cep131 is important for genome stability. <i>Development (Cambridge)</i> , 2013, 140, e207-e207. | 2.5 | 0 |
| 230 | Intratumor Heterogeneity: Seeing the Wood for the Trees. <i>Science Translational Medicine</i> , 2012, 4, 127ps10. | 12.4 | 443 |
| 231 | The centriolar satellite protein Cep131 is important for genome stability.. <i>Journal of Cell Science</i> , 2012, 125, 4770-9. | 2.0 | 92 |
| 232 | Inter and Intratumour Heterogeneity: A Barrier to Individualized Medical Therapy in Renal Cell Carcinoma?. <i>Frontiers in Oncology</i> , 2012, 2, 49. | 2.8 | 22 |
| 233 | Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. <i>EPMA Journal</i> , 2012, 3, 1. | 6.1 | 18 |
| 234 | Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. <i>EPMA Journal</i> , 2012, 3, 3. | 6.1 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 235 | Intratumor Heterogeneity: Evolution through Space and Time. <i>Cancer Research</i> , 2012, 72, 4875-4882. | 0.9 | 844 |
| 236 | Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2012, 56, 877-885. | 3.7 | 43 |
| 237 | Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer. <i>EPMA Journal</i> , 2012, 3, 6. | 6.1 | 2 |
| 238 | Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544. | 9.1 | 3,122 |
| 239 | CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. <i>Journal of Pathology</i> , 2012, 226, 482-494. | 4.5 | 48 |
| 240 | A whole-genome massively parallel sequencing analysis of <i>BRCA1</i> mutant oestrogen receptor-negative and -positive breast cancers. <i>Journal of Pathology</i> , 2012, 227, 29-41. | 4.5 | 58 |
| 241 | Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. <i>New England Journal of Medicine</i> , 2012, 366, 883-892. | 27.0 | 6,769 |
| 242 | Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. <i>Journal of Pathology</i> , 2012, 227, 146-156. | 4.5 | 92 |
| 243 | Epigenetic regulation in RCC: opportunities for therapeutic intervention?. <i>Nature Reviews Urology</i> , 2012, 9, 147-155. | 3.8 | 51 |
| 244 | Cancer chromosomal instability: therapeutic and diagnostic challenges. <i>EMBO Reports</i> , 2012, 13, 528-538. | 4.5 | 332 |
| 245 | Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics. <i>Biochemical Pharmacology</i> , 2012, 83, 1013-1020. | 4.4 | 59 |
| 246 | Recent Developments in Treatment Stratification for Metastatic Breast Cancer. <i>Drugs</i> , 2011, 71, 2099-2113. | 10.9 | 12 |
| 247 | KRAS 3'-UTR variants and stratification of breast-cancer risk. <i>Lancet Oncology</i> , The, 2011, 12, 318-319. | 10.7 | 5 |
| 248 | Breast cancer genome heterogeneity: a challenge to personalised medicine?. <i>Breast Cancer Research</i> , 2011, 13, 104. | 5.0 | 46 |
| 249 | Promoting predictive, preventive and personalised medicine: European event of global importance. <i>EPMA Journal</i> , 2011, 2, 131-136. | 6.1 | 9 |
| 250 | Chromosomal Instability Confers Intrinsic Multidrug Resistance. <i>Cancer Research</i> , 2011, 71, 1858-1870. | 0.9 | 391 |
| 251 | Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer. <i>Cancer Research</i> , 2011, 71, 3447-3452. | 0.9 | 296 |
| 252 | Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer. <i>Oncologist</i> , 2011, 16, 1535-1546. | 3.7 | 50 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 253 | Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Review of Anticancer Therapy, 2011, 11, 639-649. | 2.4 | 14 |
| 254 | Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2183-2194. | 2.5 | 141 |
| 255 | A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. Oncotarget, 2011, 2, 529-537. | 1.8 | 8 |
| 256 | Chemotherapy and metastatic breast cancer. , 2011, , 67-92. | | 0 |
| 257 | Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. Journal of Cellular Biochemistry, 2010, 111, 782-790. | 2.6 | 44 |
| 258 | A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. British Journal of Cancer, 2010, 103, 607-612. | 6.4 | 11 |
| 259 | How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. British Journal of Cancer, 2010, 103, 1139-1143. | 6.4 | 381 |
| 260 | From genomic landscapes to personalized cancer management-“is there a roadmap?. Annals of the New York Academy of Sciences, 2010, 1210, 34-44. | 3.8 | 16 |
| 261 | FKBPL Regulates Estrogen Receptor Signaling and Determines Response to Endocrine Therapy. Cancer Research, 2010, 70, 1090-1100. | 0.9 | 38 |
| 262 | Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. Current Cancer Drug Targets, 2010, 10, 799-812. | 1.6 | 28 |
| 263 | Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. Oncologist, 2010, 15, 390-404. | 3.7 | 155 |
| 264 | Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer, 2010, 46, 2166-2177. | 2.8 | 71 |
| 265 | Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncology, The, 2010, 11, 358-365. | 10.7 | 116 |
| 266 | Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Medicine, 2010, 2, 53. | 8.2 | 43 |
| 267 | Minimising Immunohistochemical False Negative ER Classification Using a Complementary 23 Gene Expression Signature of ER Status. PLoS ONE, 2010, 5, e15031. | 2.5 | 26 |
| 268 | Molecular classification of solid tumours: towards pathway-driven therapeutics. British Journal of Cancer, 2009, 100, 1517-1522. | 6.4 | 68 |
| 269 | Review: Systemic therapy for advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2009, 1, 15-27. | 3.2 | 8 |
| 270 | Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy. Cell Cycle, 2009, 8, 3262-3266. | 2.6 | 101 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 271 | RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e15. | 3.9 | 6 |
| 272 | Chromosomal instability determines taxane response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8671-8676. | 7.1 | 244 |
| 273 | Genetic prognostic and predictive markers in colorectal cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 489-499. | 28.4 | 602 |
| 274 | Unraveling the Complexity of Endocrine Resistance in Breast Cancer by Functional Genomics. <i>Cancer Cell</i> , 2008, 13, 83-85. | 16.8 | 12 |
| 275 | Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, 214. | 5.0 | 20 |
| 276 | Concordance of exon array and real-time PCR assessment of gene expression following cancer cell cytotoxic drug exposure. <i>Cell Cycle</i> , 2008, 7, 3947-3948. | 2.6 | 3 |
| 277 | Targeting Polo-Like Kinase: Learning Too Little Too Late?. <i>Journal of Clinical Oncology</i> , 2008, 26, 5497-5499. | 1.6 | 17 |
| 278 | Epothilones and new analogues of the microtubule modulators in taxane-resistant disease. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 523-546. | 4.1 | 31 |
| 279 | Initiation of High Frequency Multi-Drug Resistance Following Kinase Targeting by siRNAs. <i>Cell Cycle</i> , 2007, 6, 2001-2004. | 2.6 | 14 |
| 280 | Regulators of Mitotic Arrest and Ceramide Metabolism Are Determinants of Sensitivity to Paclitaxel and Other Chemotherapeutic Drugs. <i>Cancer Cell</i> , 2007, 11, 498-512. | 16.8 | 351 |
| 281 | The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel. <i>Cancer Cell</i> , 2007, 12, 514-527. | 16.8 | 202 |
| 282 | Principles of Targeted and Biological Therapies. , 2006, , 73-90. | | 0 |
| 283 | Anthracycline cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 791-809. | 2.4 | 108 |
| 284 | Chromosomal Instability, Colorectal Cancer and Taxane Resistance. <i>Cell Cycle</i> , 2006, 5, 818-823. | 2.6 | 73 |
| 285 | Her2-Targeted Therapies in Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4377s-4383s. | 7.0 | 63 |
| 286 | Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. <i>Acta Oncologica</i> , 2006, 45, 196-201. | 1.8 | 131 |
| 287 | Cell-cycle targeted therapies. <i>Lancet Oncology, The</i> , 2004, 5, 27-36. | 10.7 | 230 |
| 288 | RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?. <i>Lancet Oncology, The</i> , 2004, 5, 653-654. | 10.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 289 | Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products. International Journal of Experimental Pathology, 2001, 82, 3-13. | 1.3 | 42 |
| 290 | Modulation of p27Kip1 levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO Journal, 1999, 18, 654-663. | 7.8 | 141 |
| 291 | Overcoming inhibitions: subversion of CKI function by viral cyclins. Trends in Biochemical Sciences, 1999, 24, 116-120. | 7.5 | 24 |
| 292 | Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature, 1997, 390, 184-187. | 27.8 | 338 |
| 293 | APOBEC3 as a driver of genetic intratumor heterogeneity. Molecular and Cellular Oncology, 0, , . | 0.7 | 0 |